Clinical Trials · NCT02848313
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 40
- Start date
- Oct 2016
- Locations
- 1 site, United States
- Primary endpoint
- Change From Baseline in Mean Standard Luminance Best-corrected Visual Acuity (BCVA)